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ORIGINAL ARTICLE

Frequency of retinopathy of prematurity (ROP) in
infants screened for ROP: two years follow-up results
of a single center in Turkey
Adem Ugurlu*
Erzincan Binali Yildirim University, Faculty of Medicine, Department of Ophthalmology, 24100, Erzincan, Turkey

Abstract
Aim: The aim of this retrospective study was to determine the incidence of retinopathy of prematurity (ROP) in infants
referred to our clinic for screening ROP.
Material and method: The data of 729 infants who were referred to the ROP outpatient clinic of the Ophthalmology Unit
of Erzincan Binali Yildirim University, Turkey between April 2018 and March 2020 were analyzed retrospectively. The
gestational age and weight of the infants, stay in the neonatal intensive care unit, duration of oxygen therapy, and
detailed ophthalmologic examination ﬁndings were recorded in the study.
Findings and results: Of the 729 babies screened for ROP, 122 (16.7%) of them had ROP. Infants with gestational age of
≤28 weeks constitute 3.3% of all infants and ROP rate was signiﬁcantly higher than infants with older gestational age (P
< 0.001). There were 39 babies born under 1000 grams and ROP was present in 28 (71.8%) of these infants and the
incidence of ROP was higher than infants with higher birth weight (P < 0.001). With the result of logistic regression
analysis, gestational age (OR:0.592,95% CI:0.208-0.779,P < 0.001), stay in NICU (OR:0.998,95% CI:1.022-1.421,P ¼ 0.001),
and duration of oxygen (O2) therapy (OR:34.309, 95% CI:2.043-28.235,P ¼ 0.004) were detected the independent risk
factors for ROP.
Conclusion: Although infants with ≤1000 grams gestational weight and ≤28 weeks gestational age are more likely to
have ROP, it is clear that screening for all infants at risk, regardless of gestational weight and age, is very important in
preventing ROP-related vision loss. In addition, it is also recommended to control the duration of staying in neonatal
intensive care unit and oxygen therapy to as little as needed.
Keywords: Retinopathy of prematurity, Screening, Frequency

Background

R

etinopathy of prematurity (ROP) is the
name given to vasoproliferative retinal disorder that occurs in the developing retinas of
premature neonates.[1,2] The development of
retinal vessels in the fetus begins at the 16th
gestational week.[3-5] This vascular development,
which starts from the optic nerve head and progresses to the peripheral retina, reaches the nasal
ora serrata at the 36th gestational week and the
temporal ora serrata at the 40th gestational

week.[6,7] Therefore, in premature babies, the
retina is not fully vascularized at birth, and peripheral avascular zone may be present in the
retina in relation to the gestational week at
birth.[8-11] ROP is the most common cause of
preventable blindness in infants.[12,13] Therefore, as in the whole world, great importance is
attached to the screening of premature babies in
Turkey.[14,15].
In our study, it was aimed to investigate the frequency of ROP among babies who were born prematurely in the last 2 years and were referred to our
ophthalmology department for ROP screening.
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Material and method
This study was a single centre, cross-sectional,
hospital-based review of medical records of patients
referred to the Erzincan Binali Yildirim University
Mengucek Gazi Training and Research Hospital
Ophthalmology Unit ROP outpatient clinic for
screening was included in the study from April 2018
to March 2020. The data of 769 babies examined
between April 2018 and March 2020 were analyzed
retrospectively. Forty babies were excluded the
study due to the loss to follow-up. Verbally
informed consent was obtained from the parents of
all infants. The study was carried out by adhering to
the Helsinki Declaration principles. The gestational
age and weight of the infants, stay in the neonatal
intensive care unit, duration of oxygen therapy, and
detailed ophthalmologic examination ﬁndings were
recorded in the study. All of the babies included in
the study were taken non-invasive mechanical
ventilation.
ROP screening procedure
Babies smaller than 37 weeks of gestational age
were examined for ROP. All babies were examined
at 4-6 weeks after birth. ROP screening was performed after applying tropicamide 1% (Tropamid®,
Bilimilaç®,Gebze, Turkey) and phenylephrine hydrochloride 0.5% (Mydfrin®, Alcon®, Fort Worth,
TX) eye drops three times for pupillary dilatation.
ROP screening was performed by an experienced
ophthalmologist using binocular indirect ophthalmoscope combined with a scleral depressor after
applying
proparacaine
hydrochloride
0.5%
(Alcaine®, Alcon®, Fort Worth, TX) eye drops as the
topical anesthetic. The grading of the ROP status
was made according to the international ROP classiﬁcation.[1] For each infant, the status of ROP was
recorded including the zone, stage, extent of the
disease, and the presence or absence of plus disease
in the study.[8,10,12] After ROP screening procedure, each infant was also graded according to the
maximum stage of ROP in both eyes. Subjects that
were not diagnosed with ROP were followed up
every two to three weeks until retinal vascular
maturation was completed. Subjects diagnosed with
ROP were followed up every one to two weeks due
to the severeness of the disease.
Statistical analysis
IBM SPSS (Statistical Package for the Social Sciences) 22.0 package program was used to perform
statistical analysis. The average, standard deviation,
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percentage, minimum and maximum values of the
data were calculated. Chi-square test was used in
the analysis of categorical data. The normal distribution of data was calculated using the Kolmogorov-Smirnov test. Pearson correlation analysis
was used for normally distributed data for correlation analysis. If there is no normal distribution,
Spearmann correlation analysis was used for the
analysis of the data. Continuous variables were
expressed as mean ± standard deviation (SD), and
categorical variables as frequencies and percentages. The Student's t-test was performed for intergroup comparisons of the continuous variables. In
addition, the Analysis of Variation (ANOVA) test for
homogenous data and the Mann-Whitney U test for
non-homogenous data were used for statistical
analysis. To predict the signiﬁcant independent risk
factors associated with the existence of ROP, logistic
regression analysis was performed in the study. The
adjusted odds ratio (OR) and the 95% conﬁdence
interval (CI) for each possible risk factor were
calculated. Exact P values of <0.05 were accepted
statistically signiﬁcant for the analyzes.

Results
Of the 729 babies included in the study, 372 were
male and 357 were female. The mean gestational
age of infants was 33.4 ± 2.3. The mean gestational
weights of the babies were 2120.6 ± 231.9 grams.
Among the 729 babies screened, the number of
babies with ROP was 122 (16.7%). There were 7
(0.9%) babies underwent ROP treatment (4 intravitreal anti-VEGF and 3 laser photocoagulation
therapy) in the study. In infants diagnosed with
ROP, the most advanced stage of ROP was evaluated and recorded. Aggressive posterior ROP was
detected in 1 (0.8%) infant. While 18 (14.8%) infants
were stage 3, 42 (34.4%) infants were stage 2 and 61
(50%) infants in stage 1. When the ROP was ﬁrst
diagnosed in patients, 16 (13.1%) infants were zone
1, 88 (72.1%) infants were zone 2 and 18 (14.8%)
infants were zone 3 ROP. Demographic and clinical
features of the patients are shown in Table 1. The
incidence of ROP in infants according to their
gestational age and weight are shown in Tables 2
and 3, respectively.
The logistic regression analysis was performed to
determine the independent risk factors for ROP.
According to the results of this analysis, gestational
age (OR: 0.592, 95% CI: 0.208-0.779, P < 0.001), stay
in NICU (OR: 0.998, 95% CI: 1.022-1.421, P ¼ 0.001),
and duration of oxygen therapy (OR: 34.309, 95% CI:
2.043-28.235, P ¼ 0.004) were detected as the independent risk factors for ROP (Table 4).
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Table 1. Demographic and clinical features of the patients.
Number of patients
Gender(M/F)
GA (weeks)
GW (grams)
Stay in NICU
Duration O2 therapy

ROP

No ROP

Total

P value

122 (16.7%)
63(51.6%)/59(48.4%)
30.4 ± 2.2
1947.2 ± 198.4
29.8 ± 3.7 days
18.6 ± 4.5 days

607 (83.3%)
309(50.9%)/298(49.1%)
34.7 ± 1.9
2199.7 ± 251.2
5.91 ± 2.8 days
2.4 ± 1.5 days

729 (100%)
372(51%)/357(49%)
33.4 ± 2.3
2120.6 ± 231.9
8.93 ± 4.56 days
4.72 ± 3.57 days

<0.001
0.879
0.003
<0.001
<0.001
<0.001

GA:Gestational age GW:Gestational weight NICU:Neonatal intensive care unit M:male F:female.

Table 2. The incidence of ROP in our patients according to their gestational age.
Gestational age

Total n (%)

ROP n (%)

No ROP n (%)

P value*

28 weeks
29-31 weeks
32-35 weeks
35 weeks
Total

24 (3.3%)
129 (17.7%)
488 (66.9%)
88 (12.1%)
729 (100%)

17 (70.8%)
36 (27.9%)
64 (13.1%)
5 (5.7%)
122 (16.7%)

7 (29.2%)
93 (72.1%)
424 (86.9%)
83 (94.3%)
607 (83.3%)

<0.001
<0.001
<0.001
<0.001

*

Difference between the infants with and without ROP.

Table 3. The incidence of ROP in our patients according to their gestational weights.
Gestational weight

Total n (%)

ROP n (%)

No ROP n (%)

P value*

1000 grams
1001-1500 grams
1501-2000 grams
2001-2500 grams
2500 grams
Total

39 (4.5%)
138 (18.9%)
167 (23.2%)
199 (27%)
186 (26.3%)
729 (100%)

28 (71.8%)
38 (27.5%)
24 (14.4%)
21 (10.6%)
11 (5.9%)
122 (16.7%)

11 (28.2%)
110 (72.5%)
149 (85.6%)
178 (89.4%)
175 (94.1%)
607 (83.3%)

<0.001
<0.001
<0.001
<0.001
<0.001

*

Difference between the infants with and without ROP.

Table 4. Logistic regression analysis for independent risk factors of ROP.
Variable

OR

95% CI

P value

GW
GA
Sex
Stay in NICU
Oxygen removal
time

0.934
0.592
0.685
0.998
34.309

0.976-1.521
0.208-0.779
0.374-2.129
1.022-1.421
2.043-28.235

0.381
<0.001
0.379
0.001
0.004

GA: Gestational age GW: Gestational weight NICU: Neonatal
intensive care unit.

Discussion
Since the diagnosis and treatment of ROP requires serious clinical experience, it poses certain
difﬁculties for ophthalmologists.[16-19] Today, ROP
is detected before the serious stages with the
increasing awareness of pediatricians and parents
and in cases where treatment is required, intervention is made without delay.[20-23] In the treatment of ROP, the location and stage of the disease in
the retina is the most important factor in determining the treatment option.[24-28] In the presence

of ROP requiring treatment close to the posterior
pole, intravitreal anti-VEGF agents are considered
in the foreground, whereas when a ROP case
requiring treatment with peripheral avascular
retinal areas farther away from the posterior is
present, laser photocoagulation option is considered
in the foreground.[24,29-31].
Bas et al. tried to determine the ROP incidence,
risk factors and severity with the prospective TRROP study.[32] In this study, which included 6115
infants, it was concluded that the screening of babies with a gestational age of 34 weeks and a birth
weight of 1700 grams was suitable for our country. Our study also showed that babies with a
gestational age of 35 weeks and a gestational
weight of 2000 grams are at greater risk of
developing ROP. However, risk factors such as
systemic diseases, blood transfusion and sepsis
couldn't be evaluated enough in our study and it
makes the comparison difﬁcult with the study. The
frequency of ROP varies according to the development levels of the countries and the features of
the neonatal intensive care units. In developed

countries, ROP is predominantly a problem of
preterms born below 28 weeks, while in developing
countries it is reported that severe ROP develops
up to 34 weeks.[33-37].
In the multicentre study conducted by the Turkish
Neonatology Association in 2014, the frequency of
ROP was 42% and the frequency of advanced ROP
was 8.2% in preterm babies with very low birth
weight (<1500 grams). In this study, the frequency of
ROP in infants older than 32 weeks of gestation was
13.3% and advanced ROP was 0.4% in these infants.
Advanced ROP was found in 20 babies over 32 weeks
of gestational age, 41 babies with >1500 grams
gestational weight and 3 babies with >2000 grams
gestational weight. The results of the study showed
that advanced ROP requiring treatment may develop
in infants with higher gestational age and weight.[38].
Larsen et al. evaluated the incidence of retinopathy of prematurity in Germany.[39] They stated
that in their investigated cohorts, preterm infants
with higher GA than 30 weeks carried a very low or
no risk for developing treatment-requiring ROP
unless additional risk factors were present, and no
treatment was performed earlier postmenstrual age
than 32 weeks. And also they pointed out that these
ﬁndings are of relevance for the ongoing re-evaluation of ROP screening criteria.
In our study, the number of ROP with advanced
stage and requiring treatment are only 7 and 4 of
these babies underwent laser photocoagulation and
3 for intravitreal anti - VEGF treatment. All of these
infants were with 28 weeks of gestational age and
1000 grams of gestational weight. The reason for
the low number of advanced ROP babies requiring
treatment in our clinic is that our neonatal intensive
care unit is not an advanced treatment unit and
these babies in the risky group (having systemic
infections, blood transfusion, sepsis, etc.) are
directed to centers with advanced neonatal intensive care units. This is the major limitation of our
study.
Some of the babies referred to our clinic are
between 35-37 weeks of gestation, and are screened
for ROP. A small proportion of these babies have
ROP which is not requiring treatment, and this was
an important ﬁnding to show that ROP may be
seen in babies with over 35 weeks of gestation. ROP
screening is also important, especially in infants
who have higher gestational age and weight but
have accompanying systemic disease.[40] There
weren't any big babies especially with systemic risk
factors such as sepsis, blood transfusion, etc. In our
study and this is a limitation to compare the
studies.
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Conclusion
ROP screening and treatment, especially for babies with lower gestational age and weight will
provide great gains in combating this disease, which
is the most common cause of preventable blindness
in infants. In addition, it is also recommended to
control the infants for ROP while staying in neonatal
intensive care unit and make the oxygen therapy as
little as needed.
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